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Abstract
Pilocytic astrocytomas (PAs) are increasingly tested for KIAA1549-
BRAF fusions. We used reverse transcription polymerase chain reac-
tion for the 3 most common KIAA1549-BRAF fusions, together with
BRAF V600E and histone H3.3 K27M analyses to identify relation-
ships of these molecular characteristics with clinical features in a co-
hort of 32 PA patients. In this group, the overall BRAF fusion
detection rate was 24 (75%). Ten (42%) of the 24 had the 16-9 fusion,
8 (33%) had only the 15-9 fusion, and 1 (4%) of the patients had only
the 16-11 fusion. In the PAs with only the 15-9 fusion, 1 PA was in the
cerebellum and 7 were centered in the midline outside of the cere-
bellum, that is, in the hypothalamus (n = 4), optic pathways (n = 2),
and brainstem (n = 1). Tumors within the cerebellum were negatively
associated with fusion 15-9. Seven (22%) of the 32 patients had
tumor-related deaths and 25 of the patients (78%) were alive between 2
and 14 years after initial biopsy. Age, sex, tumor location, 16-9 fusion,
and 15-9 fusion were not associated with overall survival. Thus, in this
small cohort, 15-9 KIAA1549-BRAF fusion was associated with mid-
line PAs located outside of the cerebellum; these tumors, which are
generally difficult to resect, are prone to recurrence.
Key Words: BRAF, Gene fusion, KIAA1549-BRAF, Pilocytic
astrocytoma, RT-PCR.
INTRODUCTION
Pediatric low-grade gliomas are heterogeneous and
include the entities such as pilocytic astrocytoma (PA),
pilomyxoid astrocytoma, and diffuse fibrillary astrocytoma.
Pilocytic astrocytomas are the most prevalent, accounting for
23.5% of childhood central nervous system tumors (1). Sur-
vivals are also variable, with the 5-year survival in PAs
(World Health Organization [WHO] grade I) reported as high
as 100% when the tumor can be completely resected com-
pared with 45% in diffuse fibrillary astrocytoma (WHO grade
II) (2). Pilocytic astrocytomas are slow growing and, although
many are cured by gross total resection, approximately 20%
are located at unresectable sites such as the optic tract and
hypothalamus and therefore tend to recur (1).
Jones et al (3) described a novel fusion oncogene
comprising KIAA1549 and BRAF formed through the tandem
duplication at the 7q34 locus in 66% of PAs but not in high-
grade gliomas. This study found 3 fusion variants, which in total
account for 96% of fusion variants in the literature (3Y6). The
most common fusion is between exon 16 of KIAA1549 and
exon 9 of BRAF (63%), with less common fusion variants
including exon 15-exon 9 (23%) and exon 16-exon 11 (10%)
(3Y6). All fusions were found to have constitutive BRAF ki-
nase activity and transforming ability in NIH5T3 cell lines (3).
The constitutive kinase activity of KIAA1549-BRAF fusion
oncoprotein is caused by the loss of the BRAF autoregulatory
N-terminal domain while the C-terminal kinase domain is
retained (7). Forshew et al (8) found KIAA1549-BRAF fusion
variants in both diffuse fibrillary astrocytomas and pilomyxoid
astrocytomas, albeit at lower frequency than that observed in
PAs. The evidence for the specificity of BRAF rearrangements
for PAs is divided, with several reports suggesting no cases
of BRAF fusion proteins in a spectrum of low-grade gli-
omas, including ganglioglioma, desmoplastic infantile low-grade
glioma, dysembryoplastic neuroepithelial tumor, pilomyxoid
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astrocytoma, and pleomorphic xanthoastrocytoma (5, 9Y12), and
yet in other cohorts, BRAF rearrangements have been reported
in up to 15% of nonpilocytic low-grade gliomas (13Y15).
Subsequent research has unveiled several other rare
novel BRAF fusion genes and fusion genes involving RAF1,
another RAF kinase involved in the mitogen-activated protein
kinase (MAPK) pathway, accounting for approximately 4%
of all reported gene fusions in PAs (5, 6, 16Y19). For example,
Cin et al (6) identified the known KIAA1549-BRAF fusions,
the SRGAP3-RAF1 fusion, and described a novel fusion be-
tween FAM131B and BRAF in a large cohort of PAs. Con-
stitutive activation of BRAF in PAs can also occur through
a point mutation in the BRAF kinase domain, c.1799T9A
p.Val600Glu (commonly referred to as V600E). This muta-
tion is common in a wide variety of tumor types and has been
reported in 6.2% of PAs (15).
The KIAA1549-BRAF fusion is a useful putative di-
agnostic marker particularly for PAs, which can show the
neuropathologic features of necrosis and microvascular pro-
liferation, which are also seen in high-grade gliomas (1). It
was originally reported that there was no significant difference
in survival at follow-up of fusion-positive versus fusion-
negative PAs (3). By exploring the significance of the fusion
in a clinically relevant cohort of subtotally resected tumors
outside the cerebellum, Hawkins et al (20) subsequently found
that the KIAA1549-BRAF fusion was an independent prognos-
tic marker for significantly improved 5-year progression-free
survival for PAs, as well as grade II diffuse and pilomyxoid
astrocytomas. Younger patients with infratentorial posterior
fossa PAs tend to display a high frequency of the KIAA1549-
BRAF fusion (10, 21). Supratentorial tumors are less fre-
quently fusion positive but have an increased frequency of the
oncogenic BRAFV600E mutation (7, 13, 22). Currently, there
are clinical trials for BRAF and MAPK inhibitors for pediatric
gliomas (23).
The differential neuropathologic diagnosis for PAs in-
cludes pediatric high-grade gliomas, most of which have re-
cently been associated with histone mutations (H3.3 K27M)
(24). Thus, in addition to BRAF screening, analysis of H3.3
K27M status is a useful additional biomarker that should be
negative in a histologically confirmed PA case (24).
Here, we tested for the BRAF fusion, BRAFV600E, and
histone H3K27me3 biomarkers and attempted to correlate them
with the clinical outcome in a cohort of pediatric PA patients.
MATERIALS AND METHODS
Clinical Cohort
The cases included 32 patients. The male:female ratio
was 10:22, and the age range was 6months to 17 years 4 months.
There were 13 PAs in the cerebellum, 10 in the hypothalamus, 1
in the brainstem, 1 in the third ventricle, 1 in the fourth ventricle,
3 in the optic pathway, and 3 tumor locations were unknown
(Table 1). Adjuvant therapies included radiotherapy (50Y54 Gy
in 28Y30 fractions), chemotherapy (carboplatin, etoposide, vin-
blastine, vincristine), and proton therapy. In terms of complete-
ness of resection, 9 (38%) of 24 had a documented partial
resection, and 15 (62%) had a documented complete resection.
BRAF Fusion Reverse Transcription Polymerase
Chain Reaction
RNA was extracted from macrodissected formalin-fixed
paraffin-embedded (FFPE) sections using the RNeasy FFPE
kit following the manufacturer’s instructions (Qiagen, Man-
chester, UK). RNA was reverse transcribed to cDNA using
the High-Capacity cDNA RT kit following the manufacturer’s
instructions (Applied Biosystems, Warrington, UK). Real- time
PCR was performed using 2.5 KL of cDNA, primers, and
TaqMan probes specific for the KIAA1549 and BRAF fusion
as per Tian et al (4). Glyceraldehyde phosphate dehydroge-
nase was used as a control (Assays-on-Demand Gene Expres-
sion Product Hs02758991) using the TaqMan Gene Expression
Mastermix and the ABI 7500 Real-time PCR instrument (all
from Applied Biosystems). Primers were used at 0.9 mmol/L
final concentration and probes at 0.25 mmol/L final concentra-
tion. Polymerase chain reaction conditions were 2 minutes at
50-C, 10 minutes at 95-C, and then 50 cycles of 15 seconds at
95-C and 1 minute at 60-C.
Fluorescence In Situ Hybridization for
KIAA1549-BRAF Fusion
The BRAF fusion reverse transcription polymerase
chain reaction (RT-PCR) results were confirmed by fluores-
cence in situ hybridization (FISH) analysis in a subset of cases.
Formalin-fixed paraffin-embedded sections were deparaffinized
and pretreated using the SPOT-Light Tissue Pretreatment kit
(Invitrogen, Warrington, UK), and FISH was undertaken using
Kreatech Poseidon BRAF-KIAA1549 (7q34) Triple-Colour
Fusion probe with DAPI counterstain. At least 200 interphase
nuclei were examined by 2 analysts for each sample.
Immunohistochemistry
BRAF V600E (clone VE1) and anti-histone H3.3 K27M
rabbit polyclonal antibody (dilution 1:500, CAT No. ABE419;
Merck Millipore, Billerica, MA) immunohistochemistry were
performed as previously described (24, 25).
Statistical Analysis
The W2 test was used to determine the association of the
15-9 fusion with tumor location. Kaplan-Meier survival anal-
yses were used to assess age, sex, tumor location, 16-9 fusion,
and 15-9 fusion associations with overall survival; p G 0.05
was considered significant.
RESULTS
A cohort composed of 32 PA patients was successfully
tested using the BRAF fusion RT-PCR assay, BRAF V600E,
and histone H3.3 K27M. In the cohort of 32 patients, the
BRAF fusion was identified in 24 cases (75%). All cases were
negative for the H3.3 K27M, as expected. All tumors were
also negative for BRAF V600E (Table 1). Of the BRAF
fusion-positive cases, 10 (42%) had only the 16-9 fusion and
8 (33%) had only the 15-9 fusion. Five (21%) of the 24 pa-
tients had multiple fusions, 4 (17%) showed both the 16-9
fusion and a low-level 16-11 fusion, and 1 (4%) showed both
the 16-9 fusion and a 15-9 fusion (Table 2). One patient (4%)
exclusively had the 16-11 fusion. Multiple biopsy samples
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across different time points were available for 8 patients. In
7 (87%) of these 8 patients, the results from the multiple
biopsies were identical. In 1 (13%) of the 8 patients, both
biopsies sampled had the 16-9 fusion but the 16-11 fusion was
detected at a very low level in only one of the biopsies.
Clinical follow-up showed that 7 (22%) of the 32 pa-
tients were deceased, and 25 (78%) were alive between 2 and
14 years after initial biopsy. The deceased group had a male:
female ratio of 3:4, with an age at diagnosis range of 2 years
to 13 years 6 months.
In 2 (29%) of the 7 deceased patients, the original tumor
site was not noted. In the remaining 5 (71%) of this group, the
tumors originated in the hypothalamus/third ventricle or optic
pathway. The site of origin in the patients who were alive was
recorded in 24 cases (96%). Of these, 13 (55%) were in the
cerebellum, 8 (33%) were in the hypothalamus, and 1 each
(4%) was in the optic pathway, brainstem, or fourth ventricle.
Of the deceased group, 1 (14%) had a complete resection
and, of the remaining 6 patients (86%), the extent of surgical
resection was unknown. Of the alive group, the extent of sur-
gical resection was recorded for 23 (92%) out of 25 patients. Of
these, 8 (35%) had partial resection and 15 (65%) had complete
resection. As expected, tumor location and complete or partial
resection were significantly related in the cohort (p G 0.001).
Of the deceased group, 2 patients (28%) had recorded
adjuvant therapy: 1 received chemotherapy alone and 1 received
chemotherapy and radiotherapy. Of the alive group, 22 patients
(88%) had recorded adjuvant therapy: 2 received chemotherapy
and radiotherapy, 2 received radiotherapy, 1 received chemo-
therapy alone, 1 received chemotherapy and proton therapy, and
16 (72%) of these patients received no therapy.
The RT-PCR fusion test was positive for 5 (71%) out of
7 of the deceased group. Within this group, the type of fusion
present included 2 out of 5 with 16-9 fusion, 2 out of 5 with
16-9 and 16-11 fusions, and 1 with 15-9 fusion. Of the alive
group, 19 (76%) cases had a positive result for the RT-PCR
and, of these, 8 (42%) had the 16-9 fusion, 7 (37%) had the
15-9 fusion, 1 (5%) had only the 16-11 fusion, and 1 (5%)
was positive for both the 16-9 and the 15-9 fusions. In addition,
3 (16%) showed 16-9 fusions also with low levels of 16-11
fusions also (Table 1).
In the 5 deceased patients, 2 (40%) had multiple fu-
sions, whereas 4 (21%) out of 19 alive patients had multiple
fusions. The small numbers of patients in this cohort pre-
cluded determining relationships of the presence of multiple
fusions with clinical features and survival.
Interestingly, the 15-9 fusion was significantly associated
with tumor location in the midline outside of the cerebellum
TABLE 3. Cross-Tabulation of Tumor Location Versus 15-9 Fusion
Cross-Tabulation of Tumor Location Versus 15-9 Fusion
Not 15-9 15-9
Tumor location Cerebellum/not midline Count 12 1 13
Percentage 92.3 7.7 100.0
Not cerebellum/midline Count 8 8 16
Percentage 50.0 50.0 100.0
Total Count 20 9 29
Percentage 69.0 31.0 100.0
The 15-9 fusion is significantly associated with tumor location (W21 = 5.998; p = 0.014). This tabulation is after removal of cases classed as ‘‘negative’’; including ‘‘Negatives’’ as
‘‘Not 15-9’’ still results in a significant association.
TABLE 2. Relationships of Fusion Type With Tumor Location
Relationship of Fusion Type With Tumor Location
KIAA1549:BRAF Fusion Category
Total pLocation Negative 15-9 15-9 and 16-9 16-9 16-9 and 16-11 16-11
Third ventricle 1 1 ns
Fourth ventricle 1 1 ns
Brainstem 1 1 ns
Cerebellum 3 1 7 1 1 13 ns
Hypothalamus 4 4 2 10 0.014*
Optic pathway 1 2 3 ns
Unknown 3 3 ns
Total 8 8 1 10 4 1 32 ns
Relationship of other variables with overall survival
Age ns (0.3)
Sex ns (0.261)
Location ns (0.177)
16-9 fusion ns (0.208)
15-9 fusion ns (0.208)
*The hypothalamus is significantly associated with fusion 15-9. Pearson W2 test p G 0.05; ns, not significant.
Faulkner et al J Neuropathol Exp Neurol  Volume 74, Number 9, September 2015
 2015 American Association of Neuropathologists, Inc.870
Copyright © 2015 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
(p = 0.014) (Tables 2, 3). Tumors located in the cerebellum
were negatively associated with fusion 15-9 (p = 0.008).
Tumors in the cerebellum were not significantly associated
with fusion 16-9 (p = 0.080). Age (p = 0.300), sex (p = 0.261),
tumor location (p = 0.177), 16-9 fusion (p = 0.208), and
15-9 fusion (p = 0.208) were not significantly associated with
overall survival.
DISCUSSION
In this study of 32 PA patients, the KIAA1549-BRAF
fusion detection rate was (24 of 32) 75% overall. This is com-
parable to that in the literature, with previous studies showing
that 60% to 80% of PAs harbor BRAF fusions (10, 20). The
BRAF V600E mutation and H3K27me3 histone methylation
were not detected in the cohort.
The neuropathologic distinction of PA from malignant
glioma can be challenging because biopsies of PAs tend to be
small and show features such as necrosis and microvascular
proliferation that are also seen in high-grade gliomas (1).
Distinguishing these entities is key for appropriate treatment
and accurate prognostic information for pediatric glioma pa-
tients. The KIAA1549-BRAF fusion is increasingly used as a
diagnostic marker to aid neuropathologic diagnosis in low-
grade gliomas because of its high frequency in these tumors,
particularly PAs, and its absence in high-grade tumors such
as anaplastic astrocytoma (WHO grade III) and glioblastoma
(WHO grade IV) (15).
In our cohort, the KIAA1459-BRAF 16-9 fusion was
the most common, accounting for 42%; the 15-9 fusion
accounted for 33% and the 16-11 fusion only accounted for
4% (3Y6). Twenty-one percent of our cohort had multiple fu-
sions, with 17% showing both the 16-9 fusion and a low-level
16-11 fusion and 4% showing both the 16-9 fusion and a 15-9
fusion. Similarly, Tian et al (4) also described patients ex-
pressing more than 1 fusion variant, that is, 9% of their cohort
expressed both 16-9 and 15-9 fusions, and 3% expressed both
16-9 and 16-11 fusions. The primers used in our study were
identical to those used by Tian et al (4), so this could be a
genuine finding or a technical artifact of the assay. Taha et al
(26) reported 3 PA patients with fusions of both 16-9 and 15-9
using a different RT-PCR assay. The presence of multiple fu-
sion transcripts may be caused by the production of several
different RNA transcripts from alternative splicing or could
reflect different subpopulations of the tumor, each expressing
a different fusion isoform. In our cohort, it is unclear whether
multiple fusions may predict a worse clinical outcome because
of the small numbers with multiple fusions.
In our cohort, the KIAA1549-BRAF 15-9 fusion was
significantly associated with tumor location in the midline
(p = 0.014) and PAs located within the cerebellum were
negatively associated with fusion 15-9 (p = 0.008). There
is some evidence of tumors in the cerebellum being associ-
ated with fusion 16-9, but this does not achieve significance
(p = 0.080). Tumors located in the hypothalamus are tradi-
tionally difficult to resect; indeed, complete resection has been
reported in 94% of cerebellar PAs compared with only 3.2%
of hypothalamic and chiasmatic tumors, with an overall tumor
recurrence rate of 19% (27, 28). Our findings of an association
of fusion with tumor location were not seen in the large cohort
of PAs described by Jones et al; however, that study had only
2 out of 96 PAs that arose in the hypothalamus. In addition,
in contrast to other studies, the cohort by Jones et al (3) did
not show multiple fusions within a single tumor, raising the
possibility that this finding could be an artifact of PCR.
Other studies have shown an association between lo-
cation and BRAF alterations, but the present study is the first
to demonstrate an association between BRAF fusion subtype
and location. The KIAA1549-BRAF fusions are more com-
mon in posterior fossa PAs (10, 21), whereas supratentorial
PAs are less frequently fusion positive but have an increased
frequency of the oncogenic BRAFV600E mutation (7, 13, 22).
More specifically, Hawkins et al (20) showed that midline su-
pratentorial low-grade gliomas (which are usually unresectable)
had a higher frequency of KIAA1549-BRAF fusions than
lobar tumors.
In this study, age, sex, tumor location, 16-9 fusion, and
15-9 fusion were not significantly associated with overall
survival; however, the small sample size, absence of some
data, and small number of deaths may have precluded de-
tection of a significant association. Two previous studies
have shown that the KIAA1549-BRAF fusion is associated
with an improved outcome in pediatric low-grade gliomas
(13, 20), whereas 4 studies have reported no effect on out-
come (3, 13, 16, 27).
Currently, there are several clinical trials in glioma in-
volving agents that inhibit the MAPK pathway such as
BRAF, RAF1, and MEK inhibitors (15). Although a recent
phase II trial of sorafenib (multikinase inhibitor) in pediatric
low-grade astrocytoma was discontinued because of rapid
progression of the disease (29), combined therapy of sorafenib
and an mTOR inhibitor was successful in a single patient with
a spindle cell neoplasm harboring the KIAA1549-BRAF
fusion (30). Combination therapy may therefore be a useful
approach in molecularly targeting BRAF alterations in pe-
diatric gliomas and should be the focus of clinical trials in
this area, particularly in patients with tumors that are difficult
to resect.
The BRAF fusions are a useful diagnostic biomarker
and a potential prognostic biomarker in pediatric low-grade
glioma. In the future, the identification of BRAF fusions may
also be important for patient treatment as more targeted mo-
lecular therapies become available. It is therefore important
that a diagnostic test for these fusions is readily available in
a routine diagnostic setting. The KIAA1549-BRAF RT-PCR
assay used here is very straightforward to interpret, quick to
perform, amenable to FFPE tissue (some samples tested were
cases more than 20 years old), and also gives additional in-
formation as to the type of fusion variant identified. However,
because the RT-PCR assay detects only the 3 most common
fusion variants, there could be other fusion variants present
that are not detected by the assay such as KIAA1549-BRAF
fusions involving different exons and fusions between RAF
genes and a different gene; rare FAM131B-BRAF, SRGAP3-
RAF1, FXR1-BRAF, BRAF-MACF and QK1-RAF1 fusions
have also been described (6, 15). Together, these rare variants
not detected by the RT-PCR assay account for approximately
4% of all reported fusion variants.
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In terms of reproducibility of the RT-PCR assay, in 7
(87%) of 8 of the patients with multiple biopsies, the results
were identical, whereas in 1 (13%) of the 8 cases, the 16Y11
fusion was detected at a very low level. The reason for this
discrepancy is unclear, but it could possibly be caused by the
very low expression of the 16-11 fusion in the relatively small
tumor samples (4) or heterogeneity between the tumor sam-
ples. In terms of technical failure rate, in our initial validation
of the RT-PCR assay, 5 patients were excluded because of low
RNA concentration extracted from very small biopsy samples.
The RT-PCR is increasingly being implemented over
or alongside FISH in a diagnostic setting. This is because
FISH results are often very difficult to interpret because the
KIAA1549 and BRAF genes lie in close proximity on chro-
mosome 7q34, and it is difficult to distinguish a fusion signal
from a normal signal (4). Moreover, analysis may also be
complicated by amplification of the 7q34 region in some tu-
mors without gene fusion (10). In addition, identification of
the type of fusion present may give further prognostic infor-
mation in PAs, so an assay that can identify the fusion variant
such as RT-PCR may be useful to implement in a diagnostic
setting. Fluorescence in situ hybridization may be a useful
adjunct for cases where a fusion variant has not been identi-
fied by RT-PCR or where RNA extraction is unsuccessful.
In conclusion, we have identified KIAA1549-BRAF fu-
sions in 75% of patients with PA using an RT-PCR assay
from FFPE tissue. In our small cohort, the KIAA1549-BRAF
15-9 fusion was significantly associated with PAs located
outside of the cerebellum in the midline. This is the first study
to demonstrate an association between BRAF fusion subtype
and tumor location. Tumors of the midline are traditionally
difficult to resect and are prone to recurrence, so further re-
search is required to examine this observation in more detail.
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